Investment Philosophy
Each of our fund portfolios are deliberately sized to allow our team the appropriate time to actively support each company. Our post-investment ethos is focused on ensuring the leadership of each portfolio company has the resources and backing to help them be successful.
Current
Wellinks
Connected Health
Wellinks (formerly Convexity Scientific) empowers people in their pursuit to breathe freely by developing connected medical devices and technologies to improve respiratory wellness. The first commercial product, Flyp [FDA-cleared in 2017], is a connected, pocket-portable nebulizer designed to simplify the management of chronic respiratory conditions such as asthma and COPD. The company emphasizes direct relationships with their users and is a leader in digital engagement of the empowered healthcare consumer.
The Company was founded in 2014 and is based in New Haven, CT.
On June 10, 2021 HighCape Capital Acquisition Corp and Quantum-Si announced closing the merger previously announced on February 18, 2021
QuantumSi
Chip-Based Proteomics
Quantum-Si Incorporated (Nasdaq: QSI) is a pioneer in next generation semiconductor chip-based proteomics. The QSi ecosystem includes the necessary tools to decode the molecules of life, including tools for sample preparation, sequencing, and data analysis.
The transition from analog to digital proteomics enables a new generation of more sensitive and accurate research tools and diagnostics.
Elutia
Drug Eluting Biomaterials
At Elutia (Nasdaq: ELUT) we’re pioneering the future of patient care. Our proprietary drug-eluting biomaterial platforms stand at the forefront of medical innovation. We are dedicated to addressing the pressing challenges that can arise from medical device implant failures. By combatting post-surgical complications that impact patient outcomes and escalate medical costs, we’re ensuring patients not only recover, but thrive without compromise.
The Company completed an Initial Public Offering (IPO) in October 2020 and is based in Silver Springs, MD
Alphina Therapeutics
Utilizing discoveries and intellectual property licensed from Yale University, Alphina has developed cutting edge approaches to probe for, identify, and characterize altered states of nicotinamide adenine dinucleotide (NAD) metabolism and flux. The Company is focused on exploiting these unique metabolic defects with the goal of developing transformative therapeutics to treat various forms of cancer.
Alphina is based in New Haven, CT
Cybrexa
Oncology Development
Cybrexa is an oncology-focused platform technology company that enables antigen-independent targeting of tumors and metastases with deep tissue penetration for small molecule anti-cancer drugs. The Company’s alphalex™ technology powers new applications and combinations of existing cancer therapeutics using an elegant approach for targeted intracellular drug delivery, independent of surface antigens.
The company is based in New Haven, CT
Recent Exits
Acquired by Baxter International in 2019
Cheetah Medical
Non-invasive hemodynamic monitoring
Cheetah Medical was founded in 2001 with the mission of helping clinicians better manage their patient’s fluid status. Since then, Cheetah Medical has become a leader in non-invasive Cardiac Output and Hemodynamic monitoring with its proprietary CE-marked and FDA-cleared CHEETAH NICOM™ system.
Cheetah Medical is based in Newton, Massachusetts, with offices in Tel-Aviv, Israel and Portland, Oregon.
Exited via Initial Public Offering in 2019
TELA Bio
Soft Tissue Reconstruction
TELA Bio (NASDAQ: TELA) offers unique options for soft tissue repair. The Company’s innovative portfolio of soft tissue solutions combines layers of naturally sourced tissue with interwoven polymer to enable tissue remodeling, optimize strength and minimize foreign body response. The Company’s lead product, OviTex, a Reinforced Tissue Matrix, was designed in collaboration with surgeons and healthcare providers to address the unmet clinical and financial needs in hernia repair and abdominal wall reconstruction.
The Company completed an Initial Public Offering (IPO) in November of 2019 and is based in Malvern, Pennsylvania.
Acquired in December 2019
Zipline Medical
Post-Surgical Wound Closure
ZipLine Medical is an innovator in cost-effective, non-invasive surgical skin closure devices that deliver high patient satisfaction and surgeon efficiency. Zip Surgical Skin Closure devices have been used in more than 100,000 cases and in over 30 countries worldwide.
ZipLine is headquartered in Campbell, CA.
Acquired by Merck in 2024
Modifi Biosciences
New Haven, CT
Modifi Biosciences is a bold and innovative biotech company developing a novel oncology therapeutics platform that exploits DNA defects in a wide range of cancer cells, and which aims to disrupt conventional oncology drug development. This entirely new approach to fighting cancer is based on the Company’s ability to modify tumor DNA in a manner that is irreparable to cancer cells, without negatively impacting healthy cells.
Previous Exits
Acquired By Shire Pharmaceuticals
Advanced BioHealing
Regenerative Medicine
Advanced BioHealing is a leading regenerative medicine company that develops, manufactures and commercializes living cell-based therapies for regenerative medicine. Advanced BioHealing has over 400 full time employees based in the US, including an in-house commercial team of over 150 professionals comprising sales, marketing, reimbursement and policy professionals with backgrounds in the pharmaceutical, medical device and biotechnology industries. The Company’s lead product, Dermagraft® is used to treat Diabetic Foot Ulcer.
Based in La Jolla, CA
Acquired by Bio-Techne Corporation
CyVek
Immunoassay Technology
CyVek has developed a transformative immunoassay technology, CyPlex™, which integrates an innovatively designed microfluid cartridge with a state-of-the-art analyzer to deliver the most advanced and efficient bench top immunoassay system. Cyplex’s ability to provide “sample to answer” test results precisely and quickly in a sealed disposable device makes it a very attractive platform for both research and clinical applications. The CyPlex technology has the potential for broad market applicability.
Based in New Haven, CT
Acquired by Linden Capital Partners
Collagen Matrix Inc.
Tissue Repair and Regeneration
Since its inception in 1997 Collagen Matrix Inc. has been passionate about advancing the science of tissue repair and regeneration. That’s why the Company is a driving force in the design, development and manufacturing of advanced collagen and mineral based medical devices that support the body’s natural ability to regenerate. Through its proprietary technologies and innovative products, the company has commercialized over 50 medical devices in of Dental, Spine, Orthopedic, Dural Repair and Nerve Repair applications. The company employs over 200 employees in two facilities in Oakland and Allendale, NJ.